Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...

Drugs from Ionis and Arrowhead Pharma that block ... and ultra-rare disorder familial chylomicronaemia syndrome (FCS). At ACC, Ionis reported results from the phase 3 BALANCE trial of its ...

Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring new frontiers ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

GE HealthCare (Nasdaq: GEHC) today announced the U.S. launch of Flyrcado™ (flurpiridaz F 18) injection at the 2025 American ...

Novo Nordisk’s diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular ...

PAD is considered the first and most frequent manifestation of cardiovascular disease in patients with diabetes. There are few therapeutic and interventional options for patients ...

The ACC, founded in 1949, is an academic society for cardiologists and researchers and is the world’s most prestigious cardiology society that leads the latest cardiovascular research, treatments, new ...